A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment. Publishing in Nature Immunology, ...

A new Phase I clinical trial provides proof of concept for a potential therapy for treatment-resistant cancers, particularly ...

Some patients treated with immunotherapy may develop lifelong endocrine conditions requiring ongoing hormone replacement, insulin therapy and long-term monitoring, according to Vi ...

Across the immunity cycle, NPs can co-deliver tumor antigens and adjuvants to DCs, enhance major histocompatibility complex class I (MHC-I)-mediated cross-presentation, and promote cytotoxic T ...

Immune system activation and activity is regulated through stimulatory or inhibitory ligand-receptor interactions collectively termed immune checkpoints. 1 Stimulatory interactions give the immune ...

Checkpoint inhibitors are a groundbreaking class of cancer treatment, but they come with two frustrating challenges. In some cases, tumors show no initial response, rendering the therapy ineffective ...

Although cancer immunotherapy has transformed treatment by harnessing the immune system to eliminate tumors, only a small ...

Patients being treated with immune checkpoint inhibitors may be at higher risk for developing uveitis, according to a speaker ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering ...